NEIL KUMAR - 21 Dec 2022 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
CEO and President, Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
21 Dec 2022
Net transactions value
$0
Form type
4
Filing time
21 Dec 2022, 18:58:53 UTC
Previous filing
18 Nov 2022
Next filing
06 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Sale -200,000 -17% 995,686 21 Dec 2022 See Footnote F1, F2
holding BBIO Common Stock 4,813,197 21 Dec 2022 Direct
holding BBIO Common Stock 1,612,722 21 Dec 2022 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer's common stock was valued at $8.26 per share for the purposes of determining the number of shares of the exchange fund issuable to the reporting person.
F2 The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F3 The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.